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Abstract
Dengue is a mosquito-borne viral disease with a global prevalence. It is caused by four closely-related dengue viruses
(DENVs 1–4). A dengue vaccine that can protect against all four viruses is an unmet public health need. Live attenuated
vaccine development efforts have encountered unexpected interactions between the vaccine viruses, raising safety
concerns. This has emphasized the need to explore non-replicating dengue vaccine options. Virus-like particles (VLPs) which
can elicit robust immunity in the absence of infection offer potential promise for the development of non-replicating
dengue vaccine alternatives. We have used the methylotrophic yeast Pichia pastoris to develop DENV envelope (E) protein-
based VLPs. We designed a synthetic codon-optimized gene, encoding the N-terminal 395 amino acid residues of the DENV-
2 E protein. It also included 5’ pre-membrane-derived signal peptide-encoding sequences to ensure proper translational
processing, and 3’ 66 His tag-encoding sequences to facilitate purification of the expressed protein. This gene was
integrated into the genome of P. pastoris host and expressed under the alcohol oxidase 1 promoter by methanol induction.
Recombinant DENV-2 protein, which was present in the insoluble membrane fraction, was extracted and purified using Ni2+-
affinity chromatography under denaturing conditions. Amino terminal sequencing and detection of glycosylation indicated
that DENV-2 E had undergone proper post-translational processing. Electron microscopy revealed the presence of discrete
VLPs in the purified protein preparation after dialysis. The E protein present in these VLPs was recognized by two different
conformation-sensitive monoclonal antibodies. Low doses of DENV-2 E VLPs formulated in alum were immunogenic in
inbred and outbred mice eliciting virus neutralizing titers .1:1200 in flow cytometry based assays and protected AG129
mice against lethal challenge (p,0.05). The formation of immunogenic DENV-2 E VLPs in the absence of pre-membrane
protein highlights the potential of P. pastoris in developing non-replicating, safe, efficacious and affordable dengue vaccine.
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Author Summary
Dengue, a viral disease spread to humans by mosquitoes, is
endemic to more than a hundred countries. There are four closely
related dengue viruses (DENVs) that cause this disease and a
preventive vaccine to protect against all four is actively sought.
Unexpected hurdles, in weakened virus vaccine development
which revealed potential safety risk issues, has spurred renewed
interest in non-viral dengue vaccines. Infectious genetic material-
free virus-like particles (VLPs), composed only of the viral coat
proteins can induce robust immunity without causing infection.
Using recombinant DNA technology, we have created non-
infectious DENV VLPs made of only the major DENV envelope
protein important for eliciting virus-specific immunity, but lacking
the pre-membrane protein implicated in induction of disease-
enhancing antibodies. These VLPs elicit very high levels of virus-
neutralizing antibodies which protected mice significantly against
lethal DENV challenge. The encouraging data obtained for VLPs
specific to one of the four DENVs warrant the development of
VLPs specific to the remaining three. The use of the high yielding
yeast system for producing these VLPs holds great promise for the
development of dengue vaccine that may be not only safe and
efficacious but also inexpensive, for use in the resource-poor
nations where dengue is endemic.
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Introduction
Dengue is an arboviral disease, which threatens almost half the
global population, and has emerged as the most significant of
current global public health challenges [1,2]. It is spread to
humans by mosquitoes, and is caused by four closely related, but
antigenically distinct, serotypes of dengue viruses (DENV-1, -2, -3
and -4), all of which belong to the genus Flavivirus, of the family
Flaviviridae [3]. Dengue is prevalent in over a hundred, mostly
economically resource-poor, tropical and sub-tropical countries
that collectively represent .2.5 billion people. According to the
World Health Organization, there are ,50 million DENV
infections each year globally, of which ,500,000 result in severe
disease, claiming,12,500 lives [4]. A prophylactic dengue vaccine
has remained elusive, mainly because of the complex pathology of
the disease which mandates a successful vaccine to confer
simultaneous immunity against all four DENV serotypes.
DENV infections may be asymptomatic or manifest a spectrum
of clinical disease ranging from mild, self-limiting dengue fever to
severe and potentially fatal dengue hemorrhagic fever (DHF) and
dengue shock syndrome (DSS). Aside from high fever, DHF/DSS
is characterized by very high levels of viremia, thrombocytopenia,
abnormal hemostasis and vascular leakage due to endothelial
damage and in the absence of medical attention can result in very
high case fatality rates [1,3,4]. While infection with any DENV
serotype can provide durable long-lasting homotypic immunity
[5], it tends to predispose patients to severe dengue disease upon
subsequent infection with a heterotypic DENV [6]. Cross-reactive
antibodies from a prior infection are implicated in facilitating
increased uptake of heterotypic DENVs by Fc receptor-bearing
monocytes and macrophages through antibody-dependent en-
hancement (ADE) leading to higher viral load and severe disease
[3,7]. As partial immunity can potentially sensitize a vaccinee to
severe disease, a safe dengue vaccine must be tetravalent, capable
of providing durable immunity simultaneously to all four DENV
serotypes. Multiple approaches are being pursued towards
developing a safe and efficacious dengue vaccine. These include
live attenuated vaccines (LAVs), purified inactivated virus
vaccines, plasmid- and viral vector-based vaccines, and recombi-
nant subunit vaccines [2,8–10]. Of these, the LAVs are in
advanced stages of development with one of these, the chimeric
yellow fever vaccine vector-based dengue vaccine (CYD), currently
in phase III trials. However, LAVs pose unique challenges arising
from replication interference between the monovalent LAVs in
tetravalent formulations, resulting in reduced neutralizing anti-
body titers to some DENV serotypes [8,11,12]. As a result, there is
now renewed interest in non-replicating dengue vaccines [8].
One approach to non-replicating dengue vaccines may be based
on virus-like particles (VLPs). Many viral coat proteins [13],
including those of DENV [14–17], when expressed in heterolo-
gous hosts, manifest an intrinsic propensity to self-assemble into
VLPs that are similar to the parent virions. These VLPs have
unique advantages as vaccine antigens. Their architecture that
presents a high density of repetitive epitope arrays make them
highly immunogenic. In addition, their lack of infectious viral
genome makes them safe [18,19]. Thus, these VLPs offer the
means to trigger a robust immune response in the absence of any
infection. This has been borne out by the success of VLP vaccines
against hepatitis B and human papilloma virus infections [13].
For DENV, it has been shown that co-expression of two
structural proteins, the pre-membrane (prM) protein and the
envelope (E) glycoprotein, can result in the generation of discrete
VLPs in yeast [14,15], insect [16] and mammalian [17] expression
hosts. Of these two DENV structural antigens, the E glycoprotein
is the key vaccine immunogen. It is a large protein of about 500
amino acid (aa) residues, organized into three discrete domains
and held together by six S-S bridges [20], and constitutes the
major structural component of the virion surface [21]. It is a
multifunctional protein involved in host receptor recognition and
host membrane fusion during infection of susceptible cells, and the
major target of virus-neutralizing antibodies elicited during a
natural infection [3,22]. On the other hand, the prM protein
which has a role in virus maturation [22] has been implicated in
the elicitation of antibodies that can mediate ADE [23,24]. We
used the N-terminal 80% of the DENV-2 E molecule (also known
as the ectodomain), as reports in the literature have indicated that
deletion of the C-terminal hydrophobic membrane anchor stem
region enhances its immunogenicity [25]. We expressed recom-
binant DENV-2 E ectodomain, lacking the C-terminal 100 aa
residues of full length E (referred to as DENV-2 E, henceforth for
simplicity) using the methylotrophic yeast Pichia pastoris. We have
used this yeast to express other S-S linked native [26] and chimeric
[27] viral antigens that manifest self-assembly into VLPs.
Importantly, from the perspective of inexpensive vaccine devel-
opment, especially for use in resource-poor countries, it offers
several advantages including the availability of a very strong
methanol-inducible alcohol oxidase 1 (AOX1) promoter, cultiva-
tion to very high cell density in simple inexpensive media, the
capacity for high productivity and the ability to perform post-
translational modifications [28]. Surprisingly, despite the many
advantages offered by P. pastoris, it has not been exploited
effectively so far for the production of DENV E antigens for use
as sub-unit vaccines (Table S1).
In this work, we have sought to explore the utility of P. pastoris as
an expression host for developing dengue sub-unit vaccines.
Specifically, we have addressed the following questions: Can
DENV-2 E be expressed efficiently in this yeast? Would it self-
assemble into VLPs in the absence of prM? If it did, would such
VLPs be useful as potential subunit vaccines? We report for the
first time that DENV-2 E protein indeed assembles into discrete
VLPs without prM. We further present data demonstrating the
immunogenicity and protective efficacy of these DENV-2 E VLPs
using small animal models.
Methods
Ethics statement
Animal experiments were performed in accordance with
National animal ethics guidelines of the Government of India
after approval by Institutional Animal Ethics Committees of
International Centre for Genetic Engineering & Biotechnology,
New Delhi, Ranbaxy Research Laboratories, Gurgaon, and
Abexome Biosciences, Bangalore.
DENV-2 E gene, cells, viruses, antibodies and other
reagents
The DENV-2 E gene (,1.4 Kb, GenBank accession no:
JX292265), codon-optimized for P. pastoris expression, was
obtained from GenScript (New Jersey, USA). P. pastoris expression
host (strain KM71H) and the integrative plasmid pPICZ-A were
purchased from Invitrogen Life Technologies (Carlsbad, USA).
The plasmid provides the methanol-inducible AOX1 promoter for
heterologous gene expression. The viruses DENV-1, DENV-2,
DENV-3 and DENV-4 have been described before [29]. Cell lines
Vero, BHK 21 and C6/36 were from American Type Culture
Collection (ATCC), Virginia, USA. The U937 cell line expressing
dendritic cell-specific intercellular adhesion molecule 3-grabbing
non-integrin (DC-SIGN) has been reported before [30]. Ni NTA
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Super-flow resin, Ni-NTA His-Sorb plates and anti-His monoclo-
nal antibody (mAb, 34660) were purchased from Qiagen (Hilden,
Germany). DENV-2 EDIII-specific mAb 24A12 was generated in-
house [31]. Pan-DENV prM-specific 2H2 mAb has been reported
earlier [32]. Pan-DENV E-specific 4G2 mAb was from ATCC.
Anti-mouse IgG antibody-horseradish peroxidase (HRPO) and -
fluorescene isothiocyanate (FITC) conjugates were from Calbio-
chem, La Jolla, CA. Concanavalin A (Con A) –HRPO conjugate,
the HRPO substrate 3, 39, 5, 59-Tetramethylbenzidine and acid-
washed glass beads (425–600 microns) were from Sigma-Aldrich,
St. Louis, MO. Alexa Fluor 488 for labeling mAbs was from Life
Technologies (Molecular Probes, Inc). Uranyl acetate was from
TAAB Laboratories Equipment Ltd (UK). BCA protein assay
reagent was from Thermo Scientific, Rockford, USA.
Generation of DENV-2 E-expressing P. pastoris clone
The synthetic DENV-2 E gene was cloned under the control of
AOX1 promoter of pPICZ-A vector and integrated into the host
genome of P. pastoris strain KM71H. Transformants obtained
through zeocin selection were screened for DENV-2 E gene
integration [33] and its expression [34], as described before.
Induction of expression and preparation of extracts
Yeast cultures grown to logarithmic phase in buffered glycerol-
containing medium (BMGY) were induced in 1% methanol-
containing medium (BMMY) for 72 hours. Induced cells (,100
OD600) were lysed using glass beads and separated into
supernatant (S) fraction and pellet (P). The latter was extracted
in 6 M guanidine-HCl (GuHCl). The S and P fractions were
analyzed for the presence of the recombinant DENV-2 E antigen
by Western blot assay. Relative levels of recombinant DENV-2 E
protein were assessed by His-Sorb ELISA using mAb 24A12 [34].
Ni2+-affinity purification of recombinant DENV-2 E
protein
Induced cell pellet obtained from 3L starting culture was
washed in sterile 16 phosphate buffered saline (PBS), re-
suspended in 300 ml cell suspension buffer, CSB (50 mM Tris-
HCl (pH 8.5)/500 mM NaCl), and lysed with glass beads in a
Dynomill. The lysate was spun down to separate out the
membrane-enriched P fraction and stirred in membrane extrac-
tion buffer MEB (CSB supplemented with 6 M GuHCl and
30 mM imidazole) for ,4 hours at room temperature. The
resultant extract was clarified by centrifugation (13,000 rpm, 1
hour, 4uC) and filtration (0.45 m), and bound to Ni2+-NTA resin
(25 ml of a 50% slurry, pre-equilibrated in MEB) in batch mode
and packed into a chromatographic column connected to an
AKTA purifier. The column was washed extensively with MEB to
replace 6 M GuHCl with 8 M urea, and eluted using a step
imidazole gradient in 8 M urea-MEB. Column fractions contain-
ing purified protein, based on SDS-PAGE analysis, were pooled
and dialyzed against 20 mM Tris-HCl (pH 8.5) buffer containing
50 mM NaCl.
Characterization of recombinant DENV-2 E protein
Recombinant DENV-2 E protein in crude extracts (S and P
fractions), chromatographic column fractions and purified protein
preps was analyzed by SDS-PAGE and Western blotting, using
either mAb 24A12 or penta-His mAb, in conjunction with anti-
mouse IgG-HRPO conjugate. The purified DENV-2 E protein
was also analyzed in ELISA using either 3H5 or 4G2 mAbs.
Glycosylation of recombinant DENV-2 E was assessed by ELISA
and protein blot using Con A-HRPO conjugate. For both HRPO
conjugates, TMB substrate was used for color development. To
assess VLP formation, the purified protein (adjusted to a
concentration of 5–10 mg/ml in 20 mM Tris-HCl, pH 8.5,
containing 50 mM NaCl) was negatively stained with 1% uranyl
acetate and examined under a Tecnai electron microscope as
before [27].
Mouse immunization
Immunizations were performed using groups of 6–8 weeks old
Balb/C (n = 6), Swiss Albino (n = 6), and AG129 (n = 4–6) mice.
The mice were immunized intra-peritoneally (i.p) with recombi-
nant DENV-2 E VLPs. In all cases, immunization comprised three
doses given on days 0, 30 and 90. Routine immunization dose was
20 mg antigen coated on 500 mg alum (in 100 ml 16PBS). In some
experiments, lower antigen doses were also tested. Sera were
obtained ,7–10 days after each boost for analysis of antibody
titers. Balb/C and Swiss Albino immunizations were carried out at
Abexome Biosciences (Bangalore, India). AG129 experiments
were carried out at Ranbaxy Research Laboratories and ICGEB.
Analysis of antibodies by ELISA and immunofluorescence
assay
Antibody titers in murine sera were determined using indirect
ELISAs with either recombinant protein antigens (DENV-2 E
VLPs, EDIII-1, EDIII-2, EDIII-3 and EDIII-4) or with DENVs
(DENV-1, DENV-2, DENV-3 and DENV-4) as coating antigens.
The ability of antibodies induced by DENV-2 E VLPs to
recognize DENV-2 was analyzed by immunofluorescence. Briefly,
DENV-2-infected BHK-21 cells were fixed and probed with a
pooled serum (1:50 diluted) from DENV-2 E VLP-immunized
Balb/C mice. Virus-bound antibodies in the DENV-2-infected
cells were detected using secondary anti-mouse IgG-FITC
conjugate and visualized by fluorescence microscopy.
FACS based neutralization assay
A FACS-based virus neutralization assay that uses either Vero
or DC-SIGN-expressing U937 cells [30] was used to determine
DENV-neutralizing antibody titers (both homotypic as well as
heterotypic) in the sera of immunized mice. The DENVs used in
this assay were the WHO reference strains described earlier [30].
Virus-infected cells were identified using mAb 2H2-Alexa 488
conjugate. The serum dilution capable of causing a 50% reduction
in the number of DENV-infected cells compared to that in the
absence of immune serum is designated as FACS Neutralization
Titer (FNT50).
Assessment of protective efficacy of DENV-2 E VLP
immunization
A challenge model based on AG129 mouse was developed using
a previously published method [35]. To set up this model, an
Indian DENV-2 isolate was passaged alternately between C6/36
cells and AG129 mice through multiple cycles. During the course
of these cycles the virus was tested on AG129 mice for its potential
to induce signs of sickness and cause death (Figure S1). Once an
adequate stock of virulent virus was obtained, a dose-response
experiment was set up to identify a dose that resulted in 100%
lethality within a week post-challenge.
Groups of 6-8 weeks old AG129 mice were either mock-
immunized (n = 4) or immunized with 20 mg purified DENV-2 E
VLPs (n = 6) formulated in alum (i.p., days 0, 30 and 90). Ten days
after the final immunization (day 100) each mouse was adminis-
tered (i.p.) 1.46108 PFU of the challenge DENV-2 strain
produced as described above. The mice were monitored twice
Dengue Virus Envelope-Based VLP Vaccine
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daily for clinical symptoms and mortality for up to 18 days. At the
end of the experiment the data were used to generate Kaplan
Meier survival curves and analyzed by the log rank test (Mantel-
Cox) for statistical significance using GraphPad Prism software.
Additional details relating to the methods above are available
Protocol S1.
Results
Expression of DENV-2 E gene in P. pastoris
We designed a synthetic gene, DENV-2 E, codon-optimized for
expression in P. pastoris (Figure 1). This gene was placed under the
AOX1 promoter of P. pastoris to create the expression vector, pPIC-
DENV-2 E, shown in Figure 2A. This vector was integrated into
the genome of the host P. pastoris strain KM71H. Results from a
typical methanol-induction experiment performed using one of the
resultant DENV-2 E gene-harboring P. pastoris clones is shown in
Figure 2B. In this experiment, lysates were prepared from yeast
cells, either before or after methanol induction, and separated into
S and membrane-enriched P fractions. The presence of recom-
binant DENV-2 E protein in these fractions was detected by SDS-
PAGE followed by immunoblotting with DENV-2 EDIII-specific
mAb 24A12. This mAb identified a protein, with mobility
consistent with that predicted for recombinant DENV-2 E, which
appeared upon methanol-induction. Further, it was detectable
only in the P fraction. This observation was also corroborated
using a mAb specific to the 66His affinity tag (data not shown). An
ELISA wherein the recombinant protein was captured in Ni2+-
NTA coated microtiter wells and revealed using mAb 24A12 (in
conjunction with a secondary antibody enzyme conjugate),
revealed the recombinant DENV-2 E antigen to be associated
predominantly with the P fraction, as shown in Figure 2C. Next,
we sought to optimize the induction conditions so that we may
maximize recombinant DENV-2 E expression. Based on this
(Figure S2), induction for the purpose of purification was carried
out using 0.5% methanol, added every 12 hours, for a period of 3
days.
Purification of P. pastoris-expressed recombinant DENV-2
E protein
Affinity purification using the engineered 66His tag was
performed under denaturing conditions as the P. pastoris-expressed
recombinant antigen was predominantly associated with the
insoluble P fraction. Expression of recombinant DENV-2 E
protein was induced under conditions optimized above and the
resultant biomass lysed under native conditions to obtain the
membrane-enriched P fraction. This fraction, which served as the
starting material for purification, was solubilized under denaturing
conditions. Using His-Sorb ELISA, we found that the efficiency of
extraction using 6 M GuHCl was approximately twice as much as
that obtained with 8 M urea (data not shown). However, GuHCl
is not compatible with subsequent SDS-PAGE analysis of the
column fractions. Therefore, after binding to Ni2+-NTA affinity
matrix, the chromatographic column was washed extensively with
8 M urea-containing buffer and eluted using a step gradient of
imidazole. A single major peak eluted at 150 mM imidazole as
shown in Figure 3A. An SDS-PAGE analysis of column fractions
across this peak revealed a single major protein band of the
predicted size. This protein band in all these peak fractions was
also recognized by mAb 24A12 in a Western blot (Figure S3). The
peak fractions were pooled, dialyzed, and an aliquot analyzed on
SDS-PAGE, as shown in Figure 3B. This pooled material was also
tested in Western blots and found to be recognized by mAb 24A12
(Figure 3C) and a mAb specific to the 66His affinity tag (Figure
3D). The purified protein was also recognized by the conformation
sensitive mAbs 3H5 and 4G2 in ELISA (data not shown). A
protein blot using Con A-HRPO showed the purified protein to be
glycosylated (Figure 3E). Binding of DENV-2 E to Con A was also
corroborated in an ELISA format (data not shown). Based on
densitometric analysis of the blot in Figure 3B, we estimate the
Figure 1. Design of the DENV-2 E antigen. (A) Schematic representation of the DENV-2 polyprotein, showing the parts of prM and E included in
designing the E antigen for expression in P. pastoris. (B) Design of the DENV-2 E antigen consisting of the 395 aa residue E ectodomain, preceded by
the C-terminal 34 aa residues of prM. The grey box denotes the pentaglycine linker peptide joining the C-terminus of E ectodomain to the
polyhistidine tag (66H). (C) The predicted aa sequence of the DENV-2 E antigen shown in ‘B’. The color scheme corresponds to that shown in ‘B’. The
first two aa residues (MV) were introduced due to the insertion of the initiator codon in a Kozak consensus context. The downward arrows in ‘B’ and
‘C’ denote the signal cleavage site.
doi:10.1371/journal.pone.0064595.g001
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purity of the pooled and dialyzed recombinant DENV-2 E to be
,95%. We routinely obtained ,15 mg purified recombinant
DENV-2 E protein per liter of starting culture (data not shown).
As indicated earlier, we had included a 34 aa signal peptide
sequence from the C-terminal end of prM to ensure proper
processing of the E protein. As the difference between the
processed and unprocessed forms is ,4 kDa, it is not possible to
determine unambiguously if processing had occurred based on
SDS-PAGE mobility. Therefore, we analyzed the N-terminal aa
sequence of two batches of the purified DENV-2 E antigen. This
analysis revealed that processing had indeed occurred (data not
shown) at the native signal peptidase cleavage site (indicated by the
downward arrow in Figures 1B and 1C).
P. pastoris-expressed DENV-2 E possesses inherent
capacity to form VLPs
It has been reported that co-expression of prM and E proteins of
flaviviruses including DENVs [14-17] in eukaryotic host systems
leads to assembly of these two proteins into VLPs. We had
observed in the past that P. pastoris-expressed DENV-2 E
ectodomain formed VLPs when fused to the N-terminus of
Hepatitis B virus surface antigen (HBsAg) [36]. Surprisingly, we
found that deletion of the HBsAg carrier did not abrogate VLP-
forming ability of DENV-2 E. EM analysis of the purified
recombinant DENV-2 E protein preparation contained discrete
VLPs, ranging in size from 20-40 nm, as shown in Figure 4A. As
the recombinant antigen was purified under denaturing condi-
Figure 2. Expression of DENV-2 E in P. pastoris. (A) Map of the DENV-2 expression construct for integration into P. pastoris genome. The DENV-2
E gene is flanked by the AOX1 promoter (5’ AOX1) and transcription terminator (TT) at its 59 and 39 ends, respectively. The construct contains an E. coli
origin of replication (ori) and the selection marker zeocin (Zeo), which is functional in both E. coli as well as P. pastoris. (B) Localization of the
recombinant DENV-2 antigen expression in induced P. pastoris. Aliquots of un-induced (UI) and induced (I) cultures were lysed and separated into
soluble (S) and membrane-enriched pellet (P) fractions, run on SDS-polyacrylamide gel and subjected to Western blot analysis using mAb 24A12. Pre-
stained protein markers were analyzed in lane ‘M’. Their sizes (in kDa) are indicated to the left. The arrow on the right indicates the position of the
recombinant DENV-2 E antigen. (C) Ni-NTA His-Sorb ELISA analysis of S and P fractions obtained from UI (blue bars) and I (red bars) cell lysates
described in ‘B’.
doi:10.1371/journal.pone.0064595.g002
Figure 3. Purification and characterization of recombinant DENV-2 E antigen. (A) Ni2+ affinity chromatographic purification of DENV-2 E
antigen from the P fraction of induced P. pastoris lysate. The continuous blue and the dashed black curves represent the profiles of UV absorbance (at
280 nm) and the imidazole step gradient, respectively, during chromatography. (B) Coomassie-stained SDS-polyacrylamide gel analysis of the purified
protein. (C) Immunoblot analysis of the purified protein using mAb 24A12. (D) Immunoblot analysis of the purified protein using penta-His mAb. (E)
Protein blot using Con A-HRPO conjugate. Controls analyzed in parallel include DENV-2 (lane ‘V’), purified EDIII-2 protein (lane ‘III’) and ovalbumin
(lane ‘O’). In panels B-E: lanes ‘E’ denote the purified DENV-2 E protein (pooled peak material shown in panel ‘A’). Protein markers (whose sizes, in kDa,
are shown to the left of each panel) were run in lanes ‘M’. The arrow to the right of each panel indicates the position of the recombinant DENV-2 E
antigen.
doi:10.1371/journal.pone.0064595.g003
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tions, the presence of VLPs in the purified preparation indicates
that assembly of monomeric DENV-2 antigen presumably
occurred concomitant with gradual removal of urea during
dialysis. The integrity of these VLPs remained essentially intact
upon storage at 37uC for 2 weeks. In fact, the data reveal a greater
proportion of VLP homogeneity (Figure 4B). This may be a
reflection of a gradual VLP maturation event whereby greater
homogeneity is achieved, akin to a similar phenomenon reported
for hepatitis B VLPs [37].
Recombinant DENV-2 E VLPs elicit virus-specific
antibodies
Next, we investigated the immunogenicity of the DENV-2 E
VLPs above. Balb/C mice were immunized i.p. with 20 mg dose of
DENV-2 E VLPs formulated in alum using a three-dose regimen
as described in ‘Methods’, based on preliminary experiments to
assess the effect of antigen dose and boosting on antibody titers
(Figure S4). Immune sera were analyzed in an indirect ELISA
using purified DENV-2 E VLP as the coating antigen, as shown
Figure 5A. This revealed the DENV-2 E VLPs purified from P.
pastoris to be highly immunogenic. The high immunogenicity was
also evident when we substituted recombinant EDIII-2, instead of
DENV-2 E VLPs, as the coating antigen, suggesting that the
EDIII of DENV-2 E VLPs is freely accessible to anti-DENV-2
antibodies. In addition, we also observed that anti-DENV-2 E
antibodies also manifested cross-reactivity towards EDIII antigens
corresponding to the remaining three DENV serotypes (Figure
5B). Cross reactive antibody titers were approximately 20%
(EDIII-1 and EDIII-4) to 50% (EDIII-3) of the antibody titers
specific to EDIII-2. This is consistent with the presence of cross-
reactive epitopes in EDIII [38]. The high immunogenicity of
recombinant DENV-2 E VLPs seen in Balb/C was also
corroborated using Swiss albino mice, as shown in Figure 5C.
Once again, this was evident using either DENV-2 E VLP or
EDIII-2 as the coating antigen. We then tested if the antibodies
elicited by DENV-2 E VLPs could recognize and bind to DENV-
2. For this purpose, we carried out an indirect immunofluores-
cence assay, shown in Figure 5D. In this experiment, antibodies in
DENV-2 E VLP-immunized Balb/C sera recognized DENV-2
infected BHK cells, far more efficiently than antisera raised against
recombinant EDIII-2 (compare panels ii and iv, Figure 5D). The
observed pattern of fluorescence is consistent with cytoplasmic
replication of DENVs in distinct membrane associated zones.
Having shown that recombinant DENV-2 E VLPs elicit virus-
specific antibodies, we next assessed the relative homologous
versus heterologous virus-specific antibody titers. Once again, we
used the same indirect ELISA format as above, using DENV-1,
DENV-2, DENV-3 or DENV-4 as the coating antigen instead of
the recombinant protein antigens. These data, summarized in
Figure 6A reveal that heterologous virus-specific antibody titers
were ,25–50% lower compared to homologous DENV-2-specific
antibody titers, a trend mirroring the pattern observed using
recombinant EDIIIs of the four DENV serotypes, as coating
antigens (Figure 5B).
Anti-DENV-2 E VLP antibodies are potent neutralizers of
DENV-2 infectivity
As antibodies elicited by P. pastoris-expressed recombinant
DENV-2 E VLPs manifested the ability to recognize and bind
infectious DENV-2, we addressed if these antibodies may also
have the potential to block the virus infectivity in a FACS-based
virus-neutralization assay using Vero cells [30]. This assay, the
results of which are depicted in Figure 6B, revealed that
recombinant DENV-2 E VLP-induced antibodies neutralized
DENV-2 with FNT50 titers .1200. Interestingly, the neutralizing
activity appeared to be predominantly homotypic, with virtually
no effect on DENVs-1 and -3 and minimal neutralizing effect on
DENV-4. When we performed the FACS-based neutralization
assay using U937 cells engineered to express DC SIGN, DENV-2-
specific FNT50 titers were found to be ,400. As these cells also
carry Fc receptors which can mediate DENV entry, the observed
titers presumably reflect the net outcome of the dynamic balance
between neutralization and enhancement. Importantly, this
DENV-2 neutralizing activity conferred significant protection
upon AG129 mice challenged with a lethal dose of the virulent
DENV-2 strain, as shown in Figure 6C (p,0.05). The challenge
DENV-2 strain was developed in-house (Figure S1 and Protocol
S1), by adapting a previously reported method of alternate
passaging between C6/36 cells and AG129 mice [35].
Discussion
A preventive vaccine for dengue continues to be an unmet need.
Experience with LAVs which are the front runners in the dengue
vaccine development pipeline has identified significant challenges.
A major hurdle in dengue LAV development is the difficulty in
obtaining a balanced immune response against all four DENVs
due to interactions between the monovalent vaccine viruses when
administered as a tetravalent formulation [8,11,12]. Recent data
from the tetravalent CYD vaccine proof-of-concept trial in
Thailand which revealed a near total lack of efficacy against
DENV-2 [39], has served to underscore the importance of
exploring and accelerating non-replicating dengue vaccine devel-
opment efforts [8]. In this regard, genome-free dengue VLPs offer
a potentially promising alternative.
DENV E-containing VLPs produced using P. pastoris have been
documented in the literature (Table S1). However, the only
instances are when it is co-expressed with prM [14,15] or prM+C
[40]. In the current work, we have addressed the question whether
recombinant DENV-2 E by itself would possess VLP-forming
potential. We expressed recombinant DENV-2 E (lacking the C-
terminal 100 aa residues of full-length E) in P. pastoris and found it
to be associated exclusively with the insoluble membrane-enriched
P fraction, consistent with earlier studies on C-terminally deleted
variants of DENV-2 E [41] and DENV-4 E [42,43]. We purified
the protein under denaturing conditions using a single affinity
chromatographic step achieving ,95% purity and ,15 mg/L
Figure 4. Electron microscopic analysis of purified DENV-2 E
protein. (A) Freshly purified DENV-2 E antigen was negatively-stained
with uranyl acetate and examined under EM. (B) EM analysis was carried
out after incubating the purified antigen at 37uC for 2 weeks.
doi:10.1371/journal.pone.0064595.g004
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yield. Amino-terminal sequence analysis showed that the prM-
derived signal peptide was cleaved off efficiently. Also, the protein
was found to be glycosylated. Importantly, we observed that the
recombinant DENV-2 E antigen in the purified preparation
contained discrete VLPs. That this is an inherent attribute of the
DENV-2 E antigen, that happened post-expression, is suggested
by the observation that the protein was purified under strongly
denaturing conditions. Assembly into VLPs presumably occurred
upon gradual removal of the denaturant. This notion is consistent
with recent ultrastructural and immunocytochemical analyses
which strongly suggest that P. pastoris-expressed HBsAg antigen
assembles into VLPs in vitro during downstream processing [44]. It
is interesting to note that recombinant E ectodomain antigens
expressed in baculovirus-infected Sf21 cells [45] or stably
Figure 5. Evaluation of antibodies elicited by recombinant DENV-2 E antigen VLPs. (A) Pooled sera from DENV-2 E immunized (solid, blue
curve) and mock-immunized (black, dashed curve) Balb/C mice were tested in an indirect ELISA using DENV-2 E protein as the coating antigen. (B)
The Balb/C anti-DENV-2 E antiserum (panel A) was tested in ELISAs using recombinant monovalent EDIII-1 (black), EDIII-2 ( blue), EDIII-3 (red) or EDIII-4
(green) antigens. Mock-immunized Balb/C serum was tested against EDIII-1 as coating antigen (black, dashed). (C) Pooled serum from DENV-2 E-
immunized Swiss albino mice was tested in ELISAs using either recombinant DENV-2 (solid blue squares) or EDIII-2 (empty blue squares) as the
coating antigens. Mock-immunized Swiss albino serum was tested against EDIII-2 as coating antigen (black, dashed). (D) Indirect immunofluorescence
analysis of DENV-2-infected BHK cells using mock-immunized serum (i), anti-EDIII-2 antiserum (ii), 4G2 mAb (iii), or anti-DENV-2 E antiserum (iv), as the
source of primary antibodies. Bound antibodies were visualized using anti-mouse IgG-FITC conjugate. Antisera in panel (i), (ii) and (iv) were from Balb/
C mice.
doi:10.1371/journal.pone.0064595.g005
Figure 6. Characterization of DENV-2-specific antibodies elicited by DENV-2 E VLPs. (A) Analysis of virus-specific antibody titers in anti-
DENV-2 E antisera (blue bars) and mock-immune sera (black bars) in indirect ELISAs using infectious DENVs as coating antigen. (B) Determination of
virus-neutralizing antibody titers using FACS neutralization assay. Serial dilutions of anti-DENV-2 E antisera were tested for their capacity to neutralize
infectivity of all four DENV serotypes [30]. The vertical axis denotes the serum dilution corresponding to 50% neutralization (FNT50 titre) of virus
infectivity. Murine sera used in experiments shown in panels A and B were from Balb/C mice; the Arabic numerals along the x-axis, in both these
panels, indicate DENV serotype. (C) Determination of protective efficacy of DENV-2 E VLP immunization. AG129 mice were either mock-immunized
(black curve, n = 4) or immunized with DENV-2 E VLPs (blue curve, n = 6) and challenged with a virulent strain of DENV-2. The mice were monitored
daily (up to 18 days post challenge) for mortality and the resultant data plotted as Kaplan-Meir survival curves.
doi:10.1371/journal.pone.0064595.g006
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transfected Drosophila S2 cells [46] do not form VLPs. Clearly,
there are differences between the insect and yeast expression
systems, such as difference in glycosylation, which we do not
understand completely.
These VLPs were immunogenic when tested in both inbred and
outbred mice eliciting DENV-2 virus-specific antibodies. Using a
FACS-based virus neutralization assay, we observed that the
DENV-2 E VLP-induced antibodies neutralized virus infectivity
very efficiently (FNT50 titers .1:1200). Importantly, this response
was predominantly homotypic with no cross-reactivity towards
DENV-1 and DENV-3 and minimal cross-neutralizing titers to
DENV-4. The basis for this observation needs to be explored.
Recent data from Sanofi’s CYD vaccine trial have raised questions
about the validity of using Vero cells for virus-neutralization
assays, suggesting that the use of Fc receptor-bearing cells to
measure neutralizing antibody titers may be more relevant in
assessing the vaccine’s immunogenicity [39]. Repeating the
neutralization assay using U937 cells engineered to express DC-
SIGN resulted in DENV-2-specific FNT50 titers of ,400. The
lower neutralization titers observed with U937-DC-SIGN cells
suggests DENV-2 entry into cells through Fc receptors as well.
Importantly, we found in a preliminary experiment that immu-
nization with DENV-2 E VLP partially protected AG129 mice
against lethal challenge with a virulent DENV-2 strain. The level
of protection, however, was significant (p,0.05). Further exper-
iments are on to optimize antigen dose, immunization schedule,
and challenge virus dose to obtain additional data to assess the
protective efficacy of DENV-2 E VLPs.
In conclusion, we have shown that recombinant DENV-2 E
ectodomain expressed in P. pastoris undergoes post-translational
processing, enabling it to fold in a way that permits its self-
assembly into VLPs, in the absence of prM co-expression. Further,
these DENV-2 E VLPs can be produced at high levels and possess
excellent immunogenicity in different strains of mice, capable of
eliciting high titer neutralizing antibodies, using both epithelial
and Fc receptor-bearing cell substrates and capable of conferring
partial protection against lethal DENV-2 challenge in a mouse
model. The role, if any, of the DENV-2 E VLP-induced antibodies
in ADE needs to be evaluated. The data presented in this work
strongly warrant further exploration of this approach towards
developing a tetravalent dengue VLP vaccine using the P. pastoris
expression system. Work is underway to delete the 66His tag and
devise a purification strategy based on conventional chromato-
graphic methods, so that we may extend this approach to the
remaining three DENV serotypes to make a tetravalent formula-
tion. This will have the advantage of fine tuning the immune
response to each serotype, if necessary, through modification of
the relative proportions of the four monovalent VLPs.
Supporting Information
Figure S1 Evaluation of the challenge virus. Panel ‘a’
shows healthy AG129 mice. Panels ‘b’ and ‘c’ show infected mice
manifesting ruffled fur, hunched back and hind limb paralysis (day
3 post-challenge). These were administered (i.p.) 1.46108 PFU
each of the in-house developed DENV-2 challenge virus
(described in Protocol S1). Panel ‘d’ shows mice that succumbed
to virus challenge (day 5 post-challenge).
(TIF)
Figure S2 Optimization of induction of DENV-2 E
expression. (A) P. pastoris clone harboring the DENV-2 E gene
expression construct was induced at logarithmic phase of growth
with 1% methanol, followed by withdrawal of aliquots at 6 (lane 1),
12 (lane 2), 24 (lane 3), 48 (lane 4), 72 (lane 5), 96 (lane 6) and 120
(lane 7) hours post-induction. Analysis of these samples by Western
blot is shown on the top and His-Sorb ELISA on the bottom. (B)
Multiple parallel small-scale cultures of the P. pastoris clone
(described in ‘A’) were set up and each one was induced separately
with 0.5, 1 or 2% methanol for 72 hours. As in panel A, the top
and bottom parts show the Western blot and His-Sorb ELISA
results, respectively. All inductions beyond 12 hour duration were
maintained by the addition of methanol, at the appropriate
concentration, at 12 hour intervals. In the Western blots, ‘M’ and
‘U’ correspond to lanes in which protein size markers and un-
induced lysates were analyzed. The sizes of the markers (in kDa)
are shown to the left of the blots; the arrow on the right indicated
the position of the recombinant protein.
(TIF)
Figure S3 Analysis of Ni2+-NTA peak elution fractions.
(A) SDS-PAGE analysis of fractions (lanes 1–6) across the major
peak (eluting at 150 mM imidazole) shown in Figure 3A.
Separated protein bands were visualized by Coomassie staining.
(B) Western bot analysis of the same peak fractions, analyzed in
pane ‘A’. After electrophoresis, separated proteins were transferred
to a nitrocellulose membrane and probed using mAb 24A12 in
conjunction with anti-mouse IgG-HRPO plus TMB substrate. In
both panels, protein size markers were analyzed in lanes marked
‘M’. Their sizes (in kDa) are shown to the left of the panels; the
arrow to the right of each panel indicates the position of the
purified recombinant DENV-2 E protein.
(TIF)
Figure S4 Preliminary investigation of the immunoge-
nicity of recombinant DENV-2 E VLPs. (A) Analysis of
boosting effect. Balb/C mice were immunized with DENV-2 E
VLPs (20 mg formulated in alum) on days 0, 30 and 90. Sera were
collected after the first (empty blue squares) and the second (filled
blue squares) boosts, on days 37 and 100, respectively and tested
for antibody titers in indirect ELISA. (B) Determination of antigen
dose. Balb/C mice were immunized with 2 mg (green), 6 mg (red)
or 20 mg (blue) of DENV-2 E VLPs, formulated in alum, following
the same immunization schedule as in ‘A’. Sera collected after the
2nd boost (day 100) were analyzed in ELISA as before. In both
panels A and B, sera from mock-immunized mice were analyzed
in parallel (dashed black curves); in both experiments, the coating
antigen was purified DENV-2 E VLPs.
(TIF)
Table S1 DENV antigens expressed using P. pastoris.
(DOCX)
Protocol S1 Supplementary protocol details.
(DOCX)
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